Generation of Potent Antitumor CTL From Patients With Multiple Myeloma Directed Against HM1.24

Clinical Cancer Research - United States
doi 10.1158/1078-0432.ccr-04-0650
Full Text
Abstract

Available in full text

Date
Authors
Publisher

American Association for Cancer Research (AACR)

Related search

Sorafenib Has Potent Antitumor Activity Against Multiple Myeloma in Vitro, Ex Vivo, and in Vivo in the 5T33MM Mouse Model

Cancer Research
Cancer ResearchOncology
2012English

The Novel Immunotoxin HM1.24-ETA′ Induces Apoptosis in Multiple Myeloma Cells

Blood Cancer Journal
OncologyHematology
2014English

A Novel PI3K Inhibitor PIK-C98 Displays Potent Preclinical Activity Against Multiple Myeloma

Oncotarget
Oncology
2014English

Potent Antitumor Effect of Combination Therapy With Sub‑optimal Doses of Akt Inhibitors and Pomalidomide Plus Dexamethasone in Multiple Myeloma

Oncology Letters
Cancer ResearchOncology
2018English

Management of Older Patients With Multiple Myeloma

Blood Reviews
OncologyHematology
2011English

Prevalence of Apical Periodontitis in Patients With Multiple Myeloma

Medicina Oral, Patologia Oral y Cirugia Bucal
MedicineOtorhinolaryngologySurgeryDentistry
2020English

Luliconazole Demonstrates Potent in Vitro Activity Against Dermatophytes Recovered From Patients With Onychomycosis

Journal of the American Academy of Dermatology
Dermatology
2014English

GPRC5D CAR T-Cell Therapy Has Antitumor Activity in Multiple Myeloma

Cancer Discovery
Oncology
2019English

Clinical Implications of C-Maf Expression in Plasma Cells From Patients With Multiple Myeloma

Experimental Hematology and Oncology
Cancer ResearchOncologyHematology
2017English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy